gsk1120212
Stage IIIC Cutaneous Melanoma AJCC v7
National Cancer Institute (NCI)Phase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage IIIC Cutaneous Melanoma AJCC v7 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPRANOLOL Roswell Park Cancer Institute | Phase 2 | B |
Uprosertib National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →